Expanded Medicaid tied to more thyroid cancer diagnoses
Expanded Medicaid coverage was linked to the diagnosis of more thyroid cancer...Read more on AuntMinnie.comRelated Reading:
Some cancers found earlier after Medicaid expansion
Medicaid expansion tied to early breast cancer diagnosis
Medicaid expansion under ACA linked to fewer cancer deaths
Is thyroid cancer overdiagnosed for 9/11 first responders?
Medicaid expansion boosted cancer screening rates (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 18, 2020 Category: Radiology Source Type: news
17.09.20: ESMO Virtual Congress 2020:
New data reinforce strong clinical profile of Vitrakvi™ for patients of all ages with TRK Fusion Cancer including lung and thyroid tumors78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children / Majority of adverse events were grade 1 or 2; no new safety signals identified / Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively) as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) / Among patients from integ...
Source: Bayer IR Newsfeed: Events - September 17, 2020 Category: Pharmaceuticals Source Type: news
Cancer Incidence Up for Adolescents and Young Adults
2007 to 2016 saw increase in overall cancer incidence in all age groups, mainly driven by thyroid cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 17, 2020 Category: Cancer & Oncology Tags: Dermatology, Endocrinology, Family Medicine, Gastroenterology, Gynecology, Internal Medicine, Nephrology, Nursing, Oncology, Pediatrics, Journal, Source Type: news
Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to results ...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news
Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to results ...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news
